Literature DB >> 24014087

CIP2A is overexpressed in osteosarcoma and regulates cell proliferation and invasion.

Mo Zhai1, Lin Cong, Yaxin Han, Guanjun Tu.   

Abstract

Cancerous inhibitor of protein phosphatase 2A (CIP2A) is a newly characterized oncoprotein involved in a variety of malignant tumors. However, its expression pattern and biological functions in osteosarcoma remain unclear. In the present study, CIP2A expression was analyzed in 51 human osteosarcoma specimens using immunohistochemistry. CIP2A siRNA was used in the MG-63 cell line, and the effect of CIP2A depletion on cell proliferation and invasion was evaluated. We found that CIP2A was overexpressed in 76.5 % (39/51) of osteosarcoma tissues, while normal bone tissues showed negative CIP2A expression. In addition, the positive rate of CIP2A expression was higher in stage IIB osteosarcoma than stage IIA cases. Knockdown of the CIP2A expression significantly reduced osteosarcoma cell proliferation and invasion, with decreased c-Myc expression and p-AKT expression. CIP2A depletion also facilitated apoptosis and inhibited MMP9 mRNA expression. Taken together, our data identified CIP2A as a critical oncoprotein involved in cell proliferation and invasion, which could serve as a therapeutic target in osteosarcoma.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24014087     DOI: 10.1007/s13277-013-1150-z

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  40 in total

1.  CIP2A overexpression is associated with c-Myc expression in colorectal cancer.

Authors:  Camilla Böckelman; Selja Koskensalo; Jaana Hagström; Mikael Lundin; Ari Ristimäki; Caj Haglund
Journal:  Cancer Biol Ther       Date:  2012-03-01       Impact factor: 4.742

2.  Caffeine activates tumor suppressor PTEN in sarcoma cells.

Authors:  Shinji Miwa; Naotoshi Sugimoto; Toshiharu Shirai; Katsuhiro Hayashi; Hideji Nishida; Issei Ohnari; Akihiko Takeuchi; Akihiro Yachie; Hiroyuki Tsuchiya
Journal:  Int J Oncol       Date:  2011-05-23       Impact factor: 5.650

3.  Stable knockdown of S100A4 suppresses cell migration and metastasis of osteosarcoma.

Authors:  Masahiko Fujiwara; Takeshi G Kashima; Akiko Kunita; Isao Kii; Daisuke Komura; Agamemnon E Grigoriadis; Akira Kudo; Hiroyuki Aburatani; Masashi Fukayama
Journal:  Tumour Biol       Date:  2011-03-01

4.  The inhibitory effect of alendronate, a nitrogen-containing bisphosphonate on the PI3K-Akt-NFkappaB pathway in osteosarcoma cells.

Authors:  Ryosuke Inoue; Nori-aki Matsuki; Gao Jing; Takashi Kanematsu; Kihachiro Abe; Masato Hirata
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

5.  Hematopoietic stem cell function and survival depend on c-Myc and N-Myc activity.

Authors:  Elisa Laurenti; Barbara Varnum-Finney; Anne Wilson; Isabel Ferrero; William E Blanco-Bose; Armin Ehninger; Paul S Knoepfler; Pei-Feng Cheng; H Robson MacDonald; Robert N Eisenman; Irwin D Bernstein; Andreas Trumpp
Journal:  Cell Stem Cell       Date:  2008-12-04       Impact factor: 24.633

6.  c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression.

Authors:  Troy A Baudino; Catriona McKay; Helene Pendeville-Samain; Jonas A Nilsson; Kirsteen H Maclean; Elsie L White; Ann C Davis; James N Ihle; John L Cleveland
Journal:  Genes Dev       Date:  2002-10-01       Impact factor: 11.361

7.  Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer.

Authors:  Linda Soo Hoo; Jianying Y Zhang; Edward K L Chan
Journal:  Oncogene       Date:  2002-07-25       Impact factor: 9.867

8.  Association of C-MYC amplification with progression from the in situ to the invasive stage in C-MYC-amplified breast carcinomas.

Authors:  Els C Robanus-Maandag; Cathy A J Bosch; Petra M Kristel; Augustinus A M Hart; Ian F Faneyte; Petra M Nederlof; Johannes L Peterse; Marc J van de Vijver
Journal:  J Pathol       Date:  2003-09       Impact factor: 7.996

9.  Iron increases MMP-9 expression through activation of AP-1 via ERK/Akt pathway in human head and neck squamous carcinoma cells.

Authors:  Ruchadaporn Kaomongkolgit; Poonlarp Cheepsunthorn; Prasit Pavasant; Neeracha Sanchavanakit
Journal:  Oral Oncol       Date:  2007-10-23       Impact factor: 5.337

View more
  10 in total

1.  CIP2A is overexpressed and involved in the pathogenesis of chronic myelocytic leukemia by interacting with breakpoint cluster region-Abelson leukemia virus.

Authors:  Juandong Wang; Tao Huang; Jianzhi Sun; Yuan Yu; Zhifang Liu; Wenjuan Li; Jihui Jia; Chunyan Chen
Journal:  Med Oncol       Date:  2014-07-15       Impact factor: 3.064

2.  Establishment and analysis of osteosarcoma cell sublines with different metastatic characteristics.

Authors:  Zhi Li; Youjun Li; Nan Wang; Lifeng Yang; Wei Zhao; Xiandong Zeng
Journal:  Tumour Biol       Date:  2014-05-27

3.  Shikonin inhibits invasiveness of osteosarcoma through MMP13 suppression.

Authors:  Biyong Deng; Bing Qiu
Journal:  Tumour Biol       Date:  2015-06-24

4.  Expression of cancerous inhibitor of protein phosphatase 2A in human triple negative breast cancer correlates with tumor survival, invasion and autophagy.

Authors:  Shan Li; Ting-Ting Feng; Yang Guo; Xianjun Yu; Qiuyue Huang; Liang Zhang; Wei Tang; Ying Liu
Journal:  Oncol Lett       Date:  2016-11-09       Impact factor: 2.967

5.  Protein phosphatase 2A regulation of markers of extracellular matrix remodelling in hepatocellular carcinoma cells: functional consequences for tumour invasion.

Authors:  M P Ward; J P Spiers
Journal:  Br J Pharmacol       Date:  2017-04-07       Impact factor: 8.739

6.  β-Escin inhibits the proliferation of osteosarcoma cells via blocking the PI3K/Akt pathway.

Authors:  Minyu Zhu; Jinwei Ying; Chaowei Lin; Yu Wang; Kelun Huang; Yang Zhou; Honglin Teng
Journal:  RSC Adv       Date:  2018-08-21       Impact factor: 4.036

Review 7.  All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase.

Authors:  Jaya Sangodkar; Caroline C Farrington; Kimberly McClinch; Matthew D Galsky; David B Kastrinsky; Goutham Narla
Journal:  FEBS J       Date:  2015-11-14       Impact factor: 5.542

Review 8.  Regulation of PP2A by Sphingolipid Metabolism and Signaling.

Authors:  Joshua Oaks; Besim Ogretmen
Journal:  Front Oncol       Date:  2015-01-15       Impact factor: 6.244

Review 9.  Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): an oncoprotein with many hands.

Authors:  Pradip De; Jennifer Carlson; Brian Leyland-Jones; Nandini Dey
Journal:  Oncotarget       Date:  2014-07-15

10.  Overexpression of CIP2A is associated with poor prognosis in multiple myeloma.

Authors:  Xuewen Liu; Wei Cao; Shanshan Qin; Te Zhang; Junnian Zheng; Ying Dong; Pinghong Ming; Qian Cheng; Zheng Lu; Yang Guo; Baofu Zhang; Ying Liu
Journal:  Signal Transduct Target Ther       Date:  2017-05-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.